Evidence map›Paper›PMID 32143615›Full record

ArticleBMC musculoskeletal disorders2020

Serum osteocalcin level is associated with the mortality in Chinese patients with Fibrodysplasia ossificans progressiva aged ≤18 years at diagnosis.

Dunmin She, Ran Li, Ping Fang, Guannan Zong, Ying Xue, Keqin Zhang

Open access · goldAbstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dunmin SheDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China.
Ran LiDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China.
Ping FangDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China.
Guannan ZongDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China.
Ying XueDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China. doxy0622@163.com.
Keqin ZhangDepartment of Endocrinology and Metabolism, Tongji Hospital of Tongji University, Tongji University School of Medicine, No. 389, Xincun Road, Shanghai, 200065, China. 13621798084@126.com.
Tongji University · CNTongji Hospital · CN

Funding

National Natural Science Foundation of China 81400834National Natural Science Foundation of China 81670805National Natural Science Foundation of China 81974105
6 · The paper itself

Abstract

backgroundFibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by extraskeletal heterotopic ossification. It is well recognized that FOP can lead to a devastating condition of disability. However, the mortality rate of FOP patients in China and risk factors for mortality are still largely unclear.

methodsWe conducted a retrospective research on a cohort of 65 cases of FOP patients in China from 2008 to 2018. We reviewed medical records of these FOP patients to retrieve information such as date of birth/death, gender, clinical features, genotypes and biochemical parameters and analyze the correlation of these parameters with the mortality.

results92.3% (60/65 cases) patients were classic FOP patients, 3.1% (2/65 cases) were FOP-plus and 4.6% (3/65 cases) were FOP variants. 9 cases of this cohort were dead during the ten-year period, and the overall mortality rate was 13.8%. c.617G > A mutation was confirmed in all non-survivors. In FOP patients≤18 years at diagnosis, non-survivors demonstrated significantly lower blood osteocalcin and alkaline phosphatase levels compared with survivors (P < 0.05), and spearman correlation and logistic regression analysis indicated that serum osteocalcin and alkaline phosphatase levels were negatively correlated with the mortality. Furthermore, the receiver-operating characteristic curve analysis showed serum osteocalcin had the largest area under the curve of 0.855 among four biochemical parameters, and serum osteocalcin < 65.9 ng/ml displayed a good capacity to discriminate the non-survivors from survivors in FOP patients aged 18 years and younger at diagnosis.

conclusionsOur findings showed that the mortality rate of FOP was 13.8% in China. Serum OC level was negatively correlated with the mortality in Chinese FOP patients ≤18 years at diagnosis.

Indexed as

Activin Receptors, Type IAdolescentAlkaline PhosphataseChildChild, PreschoolChinaFemaleFollow-Up StudiesHumansInfantInfant, NewbornMaleMortalityMutationMyositis OssificansOssification, HeterotopicActivin Receptors, Type IACVR1 protein, humanAlkaline PhosphataseBGLAP protein, humanOsteocalcinFibrodysplasia ossificans progressiva (FOP)MortalityOsteocalcinRisk factors

Identifiers

PMID32143615
PMCPMC7060591
OpenAlexW3011349234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.